170 related articles for article (PubMed ID: 1889187)
1. Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers.
Jones RN; Pfaller MA; Allen SD; Gerlach EH; Fuchs PC; Aldridge KE
Diagn Microbiol Infect Dis; 1991; 14(4):361-4. PubMed ID: 1889187
[TBL] [Abstract][Full Text] [Related]
2. [Activity of fourth generation cephalosporins against clinical isolates of Enterobacteriaceae].
Tuchiluş C; Poiată A; Bădicuţ I; Teodor A; Luca V; Grigore L; Buiuc D
Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):595-8. PubMed ID: 14756068
[TBL] [Abstract][Full Text] [Related]
3. In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Higashi Y; Kamimura T; Matsumoto Y; Tawara S; Matsumoto F
J Antibiot (Tokyo); 1993 Jan; 46(1):71-87. PubMed ID: 8436562
[TBL] [Abstract][Full Text] [Related]
4. [In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime].
Le Noc P; Bryskier A; Le Noc D
Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):567-71. PubMed ID: 3534744
[TBL] [Abstract][Full Text] [Related]
5. Comparative activity of seven extended-spectrum cephalosporins against gram-negative bacilli from blood cultures.
Norris SM; Guenthner SH; Wenzel RP
J Antimicrob Chemother; 1985 Aug; 16(2):183-8. PubMed ID: 3934124
[TBL] [Abstract][Full Text] [Related]
6. In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies.
Sader HS; Jones RN
Eur J Clin Microbiol Infect Dis; 1994 Aug; 13(8):675-9. PubMed ID: 7813503
[TBL] [Abstract][Full Text] [Related]
7. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
[TBL] [Abstract][Full Text] [Related]
8. In-vitro antimicrobial activity of Cefpirome: a new fourth-generation cephalosporin against clinically significant bacteria.
Hafeez S; Izhar M; Ahmed A; Zafar A; Naeem M
J Pak Med Assoc; 2000 Aug; 50(8):250-2. PubMed ID: 10992706
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime.
Frei R; Jones RN; Pignatari AC; Yamane N; Marco F; Hoban DJ
Diagn Microbiol Infect Dis; 1994 Mar; 18(3):167-73. PubMed ID: 7924209
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of cefpirome compared with other third generation cephalosporins against nosocomial isolates in Argentina.
Casellas JM; Goldberg M; Orellana N; Morosini MI; Negri MC; Arduino S
Infection; 1990; 18(3):193-5. PubMed ID: 2114372
[TBL] [Abstract][Full Text] [Related]
11. New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteria.
Jones RN; Erwin ME; Bale M
Diagn Microbiol Infect Dis; 1992 Jan; 15(1):73-80. PubMed ID: 1580897
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ceftazidime and ceftriaxone.
Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.
Fuchs PC; Jones RN; Barry AL; Thornsberry C
Antimicrob Agents Chemother; 1985 May; 27(5):679-82. PubMed ID: 3893316
[TBL] [Abstract][Full Text] [Related]
14. [In vitro antimicrobial activity of cefpirome compared to other broad-spectrum beta-lactam drugs against 804 clinical isolates from 9 Brazilian hospitals].
Sader HS; Mendes CM; Montelli A; Sampaio J; Segura AJ; Kesselring GL; Costa L; Ribeiro JE; Mamizuka E; Mimiça I
Rev Assoc Med Bras (1992); 1998; 44(4):283-8. PubMed ID: 9852647
[TBL] [Abstract][Full Text] [Related]
15. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
Tumah H
Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
[TBL] [Abstract][Full Text] [Related]
16. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
Spencer RC
Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
[TBL] [Abstract][Full Text] [Related]
17. Cefpirome (HR810) disk diffusion susceptibility tests: confirmation of interpretive criteria using cefotaxime and cefoperazone-resistant strains and effects of blood supplemented media.
Jones RN; Barry AL; Thornsberry C
Diagn Microbiol Infect Dis; 1986 Apr; 4(4):345-9. PubMed ID: 3698547
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephems.
Jones RN; Erwin ME; Barrett MS; Johnson DM; Briggs BM
Diagn Microbiol Infect Dis; 1991; 14(4):301-9. PubMed ID: 1889181
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of cefepime and cefpirome compared to other third-generation cephem antibiotics against gram-negative nosocomial pathogens.
Tumah HN
Pharmazie; 2004 Nov; 59(11):854-8. PubMed ID: 15587586
[TBL] [Abstract][Full Text] [Related]
20. In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
Inoue K; Inoue E; Mitsuhashi S
Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
